Onderzoeker
Annabel Meireson
- Disciplines:Morfologische wetenschappen
Affiliaties
- Vakgroep Structuur en Herstel van de Mens (Departement)
Lid
Vanaf1 jan 2019 → 28 feb 2019 - Vakgroep Hoofd en Huid (Departement)
Lid
Vanaf1 okt 2018 → 25 sep 2022 - Vakgroep Dermatologie (Departement)
Lid
Vanaf1 okt 2016 → 30 sep 2018
Publicaties
1 - 10 van 13
- Biomarkers in immuno-oncology : from melanoma to other cancer types, from tissue to liquid biopsy, from late stage to early stage disease(2022)
Auteurs: Annabel Meireson
- Immune monitoring in melanoma and urothelial cancer patients treated with anti-PD-1 immunotherapy and SBRT discloses tumor specific immune signatures(2021)
Auteurs: Annabel Meireson, Simon Tavernier, Sofie Van Gassen, Nora Sundahl, Annelies Demeyer, Mathieu Spaas, Vibeke Kruse, Liesbeth Ferdinande, Jo Van Dorpe, Benjamin Hennart, et al.
- Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS) : study protocol for a phase 2, open-label, randomized controlled trial(2021)
Auteurs: Mathieu Spaas, Nora Sundahl, Eva Hulstaert, Vibeke Kruse, Daan De Maeseneer, Annabel Meireson, Lieve Brochez, Dries Reynders, Els Goetghebeur, Robbe Van den Begin, et al.
- IDO expression in cancer : different compartment, different functionality?(2020)
Auteurs: Annabel Meireson, Michael Devos, Lieve Brochez
- Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma(2019)
Auteurs: Nora Sundahl, Teofila Seremet, Bart Neyns, Liesbeth Ferdinande, Annabel Meireson, Lieve Brochez, Vibeke Kruse, Piet Ost
Pagina's: 828 - 835 - Phase 1 dose escalation trial of ipilimumab and stereotactic body radiation therapy in metastatic melanoma(2018)
Auteurs: Nora Sundahl, Katrien De Wolf, Vibeke Kruse, Annabel Meireson, Dries Reynders, Els Goetghebeur, Mireille Van Gele, Reinhart Speeckaert, Benjamin Hennart, Lieve Brochez, et al.
Pagina's: 906 - 915 - Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma(2018)
Auteurs: Lieve Brochez, Annabel Meireson, Ines Chevolet, Nora Sundahl, Piet Ost, Vibeke Kruse
- Peritumoral endothelial indoleamine 2,3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile
Auteurs: Annabel Meireson, Ines Chevolet, Eva Hulstaert, Piet Ost, Karen Geboes, Marc De Man, Dirk Van de Putte, Laurine Verset, Vibeke Kruse, Pieter Demetter, et al.
Pagina's: 25216 - 25224 - Endothelial indoleamine 2,3-dioxygenase is correlated with microsatellite status in colorectal carcinoma and predicts worse prognosis
Auteurs: Annabel Meireson, Ines Chevolet, Eva Hulstaert, Piet Ost, Karen Geboes, Marc De Man, Dirk Van de Putte, Laurine Verset, Vibeke Kruse, Pieter Demetter, et al.
Aantal pagina's: 1 - A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma : evaluation of safety and clinical and immunologic response
Auteurs: Nora Sundahl, Katrien De Wolf, Daan De Maeseneer, Annabel Meireson, Els Goetghebeur, Pieter De Visschere, Dries Reynders, Mireille Van Gele, Lieve Brochez, Piet Ost